Business Description
Cosmo Pharmaceuticals NV
NAICS : 325412
SIC : 2834
ISIN : NL0011832936
Share Class Description:
XSWX:COPN: Registered SharesDescription
Cosmo Pharmaceuticals NV is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology and healthtech. The company develops and manufactures products that are distributed globally by its partners. Products that the company has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers' diarrhoea (TD) and Winlevi for the treatment of acne. Product pipeline includes Breezula, GI Genius, Methylene blue MMX, Aemcolo, CB-03-10 and CB-01-33.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.27 | |||||
| Equity-to-Asset | 0.59 | |||||
| Debt-to-Equity | 0.41 | |||||
| Debt-to-EBITDA | 4.14 | |||||
| Interest Coverage | 2.98 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 3.29 | |||||
| Beneish M-Score | -2.25 | |||||
| WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 9.6 | |||||
| 3-Year Book Growth Rate | -2.2 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 43.57 | |||||
| 9-Day RSI | 51.81 | |||||
| 14-Day RSI | 54.89 | |||||
| 6-1 Month Momentum % | 92.02 | |||||
| 12-1 Month Momentum % | 20.82 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.42 | |||||
| Quick Ratio | 1.35 | |||||
| Cash Ratio | 1.11 | |||||
| Days Inventory | 243.32 | |||||
| Days Sales Outstanding | 99.04 | |||||
| Days Payable | 193.36 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 1.42 | |||||
| Dividend Payout Ratio | 1.62 | |||||
| Forward Dividend Yield % | 2.68 | |||||
| 5-Year Yield-on-Cost % | 1.42 | |||||
| 3-Year Average Share Buyback Ratio | -3.9 | |||||
| Shareholder Yield % | 3.34 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 80.53 | |||||
| Operating Margin % | 26.02 | |||||
| Net Margin % | 10.43 | |||||
| FCF Margin % | 23.02 | |||||
| ROE % | 2.38 | |||||
| ROA % | 1.42 | |||||
| ROIC % | 2.61 | |||||
| ROC (Joel Greenblatt) % | 47.57 | |||||
| ROCE % | 4.51 | |||||
| Years of Profitability over Past 10-Year | 6 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 107.85 | |||||
| Forward PE Ratio | 10.37 | |||||
| PE Ratio without NRI | 111.95 | |||||
| Shiller PE Ratio | 22.38 | |||||
| Price-to-Owner-Earnings | 172.88 | |||||
| PS Ratio | 11.21 | |||||
| PB Ratio | 2.7 | |||||
| Price-to-Tangible-Book | 29.96 | |||||
| Price-to-Free-Cash-Flow | 48.75 | |||||
| Price-to-Operating-Cash-Flow | 32.34 | |||||
| EV-to-EBIT | 39.83 | |||||
| EV-to-Forward-EBIT | 27.26 | |||||
| EV-to-EBITDA | 26.67 | |||||
| EV-to-Forward-EBITDA | 18.45 | |||||
| EV-to-Revenue | 10.78 | |||||
| EV-to-Forward-Revenue | 4.37 | |||||
| EV-to-FCF | 46.7 | |||||
| Price-to-Projected-FCF | 4.21 | |||||
| Price-to-Median-PS-Value | 0.6 | |||||
| Price-to-Graham-Number | 12.28 | |||||
| Earnings Yield (Greenblatt) % | 2.52 | |||||
| FCF Yield % | 2.05 | |||||
| Forward Rate of Return (Yacktman) % | 21.23 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cosmo Pharmaceuticals NV Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil CHF) | 102.374 | ||
| EPS (TTM) (CHF) | 0.655 | ||
| Beta | 1.59 | ||
| Volatility % | 46.83 | ||
| 14-Day RSI | 54.89 | ||
| 14-Day ATR (CHF) | 1.974303 | ||
| 20-Day SMA (CHF) | 70.975 | ||
| 12-1 Month Momentum % | 20.82 | ||
| 52-Week Range (CHF) | 33.7 - 76 | ||
| Shares Outstanding (Mil) | 16.05 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cosmo Pharmaceuticals NV Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cosmo Pharmaceuticals NV Stock Events
| Event | Date | Price(CHF) | ||
|---|---|---|---|---|
| No Event Data | ||||
Cosmo Pharmaceuticals NV Frequently Asked Questions
What is Cosmo Pharmaceuticals NV(XSWX:COPN)'s stock price today?
The current price of XSWX:COPN is CHF71.60. The 52 week high of XSWX:COPN is CHF76.00 and 52 week low is CHF33.70.
When is next earnings date of Cosmo Pharmaceuticals NV(XSWX:COPN)?
The next earnings date of Cosmo Pharmaceuticals NV(XSWX:COPN) is .
Does Cosmo Pharmaceuticals NV(XSWX:COPN) pay dividends? If so, how much?
The Dividend Yield %  of Cosmo Pharmaceuticals NV(XSWX:COPN) is 1.42% (As of Today), Highest Dividend Payout Ratio of Cosmo Pharmaceuticals NV(XSWX:COPN) was 1.62. The lowest was 0.81. And the median was 0.91. The  Forward Dividend Yield % of Cosmo Pharmaceuticals NV(XSWX:COPN) is 2.68%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers